

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2011

---

**ORAMED PHARMACEUTICALS INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-50298**  
(Commission File Number)

**98-0376008**  
(IRS Employer  
Identification No.)

**Hi-Tech Park 2/5 Givat Ram**  
**PO Box 39098**  
**Jerusalem, Israel 91390**  
(Address of principal executive offices and zip code)

**Registrant's telephone number, including area code: 972-2-566-0001**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM OTHER EVENTS****8.01**

On September 15, 2011, Oramed Pharmaceuticals Inc. issued a press release announcing that Ehud Arbit, M.D., the Director of R&D at Oramed, is scheduled to present at the 8th Annual Israel Strategic Partner and Venture Conference. The conference will be held at the Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, NJ on September 22, 2011. Dr Arbit is scheduled to speak on Thursday September 22, 2011 at 4:30 p.m. ET.

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

**ITEM FINANCIAL STATEMENTS AND EXHIBITS.****9.01**

(d) Exhibits

Exhibit Number	Description
99.1	Press Release dated September 15, 2011

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ORAMED PHARMACEUTICALS INC.**

Dated: September 15, 2011

By: /s/ Nadav Kidron

\_\_\_\_\_  
Nadav Kidron  
President, CEO and Director

---

**Exhibit Index**

Exhibit  
Number

Description

99.1

Press Release dated September 15, 2011

---

---



**Oramed Pharmaceuticals Chosen to Present at the  
8th Annual Israel Strategic Partner and Venture  
Conference on September 22, 2011**

JERUSALEM, Israel – September 15, 2011 – Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB) (<http://www.oramed.com>), a developer of oral delivery systems, announced today that Ehud Arbit, M.D., the Director of R&D at Oramed, is scheduled to present at the 8th Annual Israel Strategic Partner and Venture Conference. The conference will be held at the Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, NJ on September 22, 2011.

Dr Arbit is scheduled to speak on Thursday September 22, 2011 at 4:30 p.m. ET. This conference offers Oramed the opportunity to present its strategic initiatives, updates and product pipeline to investors, strategic partners, including pharmaceutical companies, leading venture capital firms and angel investors.

For more information about the conference please visit <http://www.blankrome.com/index.cfm?contentID=35&itemID=2153>

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. Oramed's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit <http://www.oramed.com>

---



#### Safe Harbor Statement

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the Company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the Company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the Company to differ materially from those expressed or implied in such forward looking statements. The Company undertakes no obligation to update or revise any forward-looking statements.

#### Company and Investor Relations Contacts:

Oramed Pharmaceuticals

Tara Horn

Office: 646-240-4193

Cell: +972-54-334-4318

Email: tara@oramed.com

**Oramed Pharmaceuticals Inc.** | Kefar Hi-Tech 2/5 Po Box 39098, Jerusalem, Israel 91390. | [www.oramed.com](http://www.oramed.com)

Phone: 011-972-2-566-0001 | Fax: 011 972-2-566-0004 | Email: office@oramed.com

---